Humexlib Etat Grippal (Pheniramine Maleate, Ascorbic Acid, Paracetamol)

Humexlib Etat Grippal is indicated for symptomatic relief of mild to moderate cold and influenza manifestations, helping users manage discomfort while continuing daily activities.

• Relief of headache and body aches associated with viral upper‑respiratory infections.
• Reduction of fever through antipyretic action.
• Alleviation of sore throat discomfort.
• Temporary easing of nasal congestion and runny nose caused by histamine release.
• Support of overall comfort during the early stages of a cold or flu.
• May improve sleep quality when fever or nasal symptoms disturb rest.
• Can aid in maintaining normal daily tasks during the early phase of illness.

• Pheniramine maleate acts as an H1‑histamine receptor antagonist, blocking the action of histamine released during an upper‑respiratory infection and thereby reducing nasal congestion, itching and watery secretions. Paracetamol exerts analgesic and antipyretic effects by inhibiting central cyclooxygenase enzymes, which lowers prostaglandin synthesis in the hypothalamus and pain‑processing pathways. Ascorbic acid provides vitamin C, an antioxidant that supports normal immune function but does not directly treat symptoms.

Like most combination cold remedies, Humexlib Etat Grippal may cause unwanted effects. Most reactions are mild, transient, and resolve without medical intervention, but users should be aware of the full range of possible symptoms.

Common

• Drowsiness or mild sedation.
• Dry mouth or throat.
• Nausea or mild stomach upset.
• Headache.
• Dizziness.
• Mild gastrointestinal discomfort (e.g., abdominal cramping).
• Transient visual disturbances such as blurred vision.
• Taste alteration or metallic aftertaste.

Serious

• Allergic skin reactions such as rash, itching or swelling.
• Signs of liver toxicity, including dark urine or persistent jaundice.
• Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Unusual bleeding or bruising indicating possible blood‑cell effects.
• Severe liver injury indicated by elevated enzymes or hepatic failure.

When using Humexlib Etat Grippal, certain precautions help minimize risk and ensure safe use.

• Do not exceed the recommended daily dose; excessive paracetamol can affect the liver.
• Use caution if you have a history of asthma, chronic bronchitis, or other respiratory conditions, as pheniramine may cause bronchospasm.
• Avoid the product if you are allergic to any of its ingredients, including pheniramine, paracetamol or vitamin C.
• Pregnant or breastfeeding individuals should consult a healthcare professional before use.
• Keep out of reach of children; accidental ingestion can be hazardous.
• Do not combine with other products containing paracetamol or antihistamines without professional advice.

Humexlib Etat Grippal can interact with other medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Other paracetamol‑containing products, to avoid cumulative hepatotoxicity.
• Monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI, due to possible additive central nervous system effects.
• Strong CYP450 enzyme inducers that may lower paracetamol levels, such as rifampicin.

Use with caution

• Alcohol, because combined use can increase liver strain and enhance drowsiness.
• Sedatives, antihistamines, or CNS depressants, which may intensify the drowsy effect of pheniramine.
• Anticoagulants (e.g., warfarin), as high‑dose paracetamol may affect coagulation parameters.
• Antidepressants such as tricyclics, because pheniramine may increase anticholinergic burden.